BioSpace News Archive

Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), Annexon, a clinical-stage biopharmaceutical company developing a class of new complement medicines for patients with classical complement-mediated autoimmune and neurodegenerative disorders of the body, brain and eye, today announced second quarter 2021 financial results and provided a mid-year business update.

Marrone Bio Innovations, Inc. (NASDAQ: MBII), an international leader in sustainable bioprotection and plant health solutions, has provided its financial results for the second quarter ended June 30, 2021.

STRATA Skin Sciences, Inc., a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announced the acquisition of the U.S. dermatology business of Ra Medical.

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (Acumen), a clinical stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer’s disease (AD), today reported financial results for the quarter ended June 30, 2021 and provided recent business highlights.

Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced business highlights and financial results for the three months ended June 30, 2021.

Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today reported its financial results for the three months ended June 30, 2021, and provided a business update.

Basilea Pharmaceutica Ltd. announced that it has been awarded an additional USD 4.3 million of non-dilutive funding by the Biomedical Advanced Research and Development Agency, part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, in the context of the existing contract to support the phase 3 program of Basilea’s antibiotic ceftobiprole.

Sino Biological, Inc., a biotechnology company which provides biological research reagents and related technical contract research services, announced a successful listing on the Shenzhen Stock Exchange subsidiary ChiNext under the stock abbreviation Sino Biological and stock code 301047.

Urethral bulking is used to treat urinary incontinence. It involves injecting material, such as collagen, around the urethra.

The demand within the global market for splenomegaly therapeutics has been rising on account of advancements in the field of spleen-care.